China's Hutchison Medipharma Receives $18 Million In Payments From Eli Lilly
Hutchison MediPharma, a subsidiary of Hutchison China MediTech, will receive $18 million in payments from Lilly during this quarter as part of Lilly's in-licensing of fruquintinib. Fruquintinib is a VEGF inhibitor that has completed a Phase II trial in patients with metastatic colorectal cancer. The payments consist of a $10 million milestone for successfully completing the first fruquintinib proof-of-concept trial and $8 million to help underwrite a Phase III trial of the drug.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.